Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects

Author(s): Linda Landini*, Eleni Rebelos, Miikka-Juhani Honka

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 16 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Cardiovascular diseases (CVD) are the leading cause of death worldwide. Evidence from observational and randomized controlled studies showing the potential benefits of green tea on lowering CVD risk has been emerging rapidly during the past few decades. These benefits include reduced risk for major cardiovascular events, lowering of blood pressure, decreased LDL cholesterol levels and weight loss. At the same time, the understanding of the physiological mechanisms behind these alterations is advancing. Consumption of green tea originated from China thousands of years ago, but since then, it expanded all over the world. Recent advances in understanding the role of tea polyphenols, mainly catechins, as mediators of tea’s health benefits, have caused the emergence of various types of green tea extracts (GTE) on the market. While taking green tea is generally considered safe, there are concerns about the safety of using tea extracts. The present article reviews the current evidence of green tea consumption leading to reduced CVD risk, its potential biological mechanisms and the safety of using GTE.

Keywords: Green tea, GTE, cardiovascular disease, supplements, safety, beneficial cardiovascular effects.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 16
Year: 2021
Published on: 01 November, 2020
Page: [1931 - 1940]
Pages: 10
DOI: 10.2174/1381612826666201102104902
Price: $65

Article Metrics

PDF: 169